Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab + Zongertinib in HER2-Mutated NSCLC
NCT07899801Phase 1Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2027
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of zanidatamab and zongertinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Dose-Limiting Toxicities at 21 days and Treatment-Emergent Adverse Events. Planned start Apr 2027; status: not yet recruiting.
02
Drugs
zanidatamabzongertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07899801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07899801.